References

1. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Questions and answers about arthritis and rheumatic diseases. July 2011. Available at http://www.niams.nih.gov/Health_Info/Arthritis/arthritis_rheumatic_qa.asp (accessed on 15 July 2012).
2. Silman AJ. Rheumatoid arthritis. In: Silman AJ, Hochberg MC, eds. Epidemiology of the rheumatic diseases. Oxford Press, Oxford; 2004.
3. Winchester R, Dwyer E, Rose S. The genetic basis of rheumatoid arthritis: the shared epitope hypothesis. Rheumatic Diseases Clinics of North America. 1992; 18: 761-783.
4. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis and Rheumatism. 1998; 41: 778-799.
5. Wilder RL. Neuroimmunoendocrinology of the rheumatic diseases: past, present, and future. Annals of the New York Academy of Sciences. 2002; 966: 13-19.
6. Centers for Disease Control and Prevention. Prevalence of arthritis: United States, 1997. Morbidity and Mortality Weekly Report. 2001; 50: 334-336.
7. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001; 358: 903-911.
8. Akil M, Amos RS. ABC of rheumatology. Rheumatoid arthritis--I: Clinical features and diagnosis. BMJ. 1995; 310: 587-590.
9. Yocum DE, Castro WL, Cornett M. Exercise, education, and behavioral modification as alternative therapy for pain and stress in rheumatic disease. Rheumatic Diseases Clinics of North America. 2000; 26: 145-159.
10. Wright A, Sluka KA. Nonpharmacological treatments for musculoskeletal pain. Clinical Journal of Pain. 2001; 17: 33-46.
11. Macfarlane GJ, El-Metwally A, De Silva V, et al. Evidence for the efficacy of complementary and alternative medicines in the management of rheumatoid arthritis: a systematic review. Rheumatology. 2011; 50: 1672-1683.
12. Wang C, de Pablo P, Chen X, et al. Acupuncture for pain relief in patients with rheumatoid arthritis: a systematic review. Arthritis and Rheumatism. 2008; 59: 1249-56.
13. Lee MS, Shin BC, Ernst E. Acupuncture for rheumatoid arthritis: a systematic review. Rheumatology. 2008; 47: 1747-53.
14. Leibing E, Pfingsten M, Bartmann U, et al. Cognitive-behavioral treatment in unselected rheumatoid arthritis outpatients. Clinical Journal of Pain. 1999; 15: 58-66.
15. Pincus T, Griffith J, Pearce S, et al. Prevalence of self-reported depression in patients with rheumatoid arthritis. British Journal of Rheumatology. 1996; 35: 879-883.
16. Symmons D, Turner G, Webb R et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology. 2002; 41: 793-800.
17. Hamilton J, McInnes IB, Thomson EA, et al. Comparative study of intramuscular gold and methotrexate in a rheumatoid arthritis population from a socially deprived area. Annals of the Rheumatic Diseases. 2001; 60: 566-572.
18. Arthritis Research Campaign. Arthritis information. Available at http://www.arthritisresearchuk.org/arthritis_information.aspx (accessed on 15 June 2012).
19. Griffith J, Carr A. What is the impact of early rheumatoid arthritis on the individual? Best Practice and Research in Clinical Rheumatology. 2001; 15: 77-90.
20. Yelin E, Henke C, Epstein W. The work dynamics of the person with rheumatoid arthritis. Arthritis and Rheumatism. 1987; 30: 507-512.
21. Smith CA. Diagnosing rheumatoid arthritis: current criteria. American Family Physician. 1991; 44: 863-870.
22. Brown JH. The radiology of rheumatoid arthritis. American Family Physician. 1995; 52: 1372-1380.
23. van der Heide A, Jacobs JW, Bijlsma JW, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs: a randomized, controlled trial. Annals of Internal Medicine. 1996; 124 :699-707.
24. Hawley DJ, Wolfe F. Are the results of controlled clinical trials and observational studies of second line therapy in rheumatoid arthritis valid and generalizable as measures of rheumatoid arthritis outcome: analysis of 122 studies. Journal of Rheumatology. 1991; 18: 1008-1014.
25. Suarez-Almazor ME, Belseck E, Shea B, et al. Methotrexate for rheumatoid arthritis (Cochrane review). In: The Cochrane Library. Update Software, Oxford, UK.
26. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two metaanalyses. Arthritis and Rheumatism. 1990; 33: 1449-1461.
27. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis: a metaanalysis of published clinical trials. Arthritis & Rheumatism. 1992; 35: 1117-1125.
28. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Archives of Internal Medicine. 1999; 159: 2542-2550.
29. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet. 1999; 353: 259-266.
30. Dougados M, Combe B, Cantagrel A, et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Annals of the Rheumatic Diseases. 1999; 58: 220-225.
31. Haagsma CJ, van Riel PL, de Jong AJ, et al. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. British Journal of Rheumatology. 1997; 36: 1082-1088.
32. Case JP. Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 2: the newer drugs and drug strategies. American Journal of Therapeutics. 2001; 8: 163-179.
33. Maetzel A, Wong A, Strand V, et al. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology. 2000; 39: 975-981.
34. Weinblatt ME, Reda D, Henderson W, et al. Sulfasalazine treatment for rheumatoid arthritis: a metaanalysis of 15 randomized trials. Journal of Rheumatology. 1999; 26: 2123-2130.
35. Nuver-Zwart IH, van Riel PL, van de Putte LB, et al. A double blind comparative study of sulfasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulfasalazine. Annals of the Rheumatic Diseases. 1989; 48: 389-395.
36. van der Heijde DM, van Riel PL, Nuver-Zwart IH, et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet. 1989; 1: 1036-1038.
37. Smedegard G, Bjork J. Sulphasalazine: mechanism of action in rheumatoid arthritis. British Journal of Rheumatology. 1995; 34 (supplement 2): S7-S15.
38. Suarez-Almazor ME, Belseck E, Shea B, et al. Sulfasalazine for rheumatoid arthritis (Cochrane review). In: The Cochrane Library. Update Software, Oxford, UK.
39. Van der Heijde DM, van Riel PL, Nuver-Zwart IH, et al Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis.
40. National Institute for Health and Clinical Excellence. Rheumatoid arthritis - etanercept and infliximab December 2011. Technology appraisal 36. http://www.nice.org.uk/guidance/TA36 (accessed on 15 June 2012).
41. National Institute for Health and Clinical Excellence. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. October 2011. Technology appraisal guidance 130. Available at http://www.nice.org.uk/TA130 (accessed on 15 June 2012).
42. Blumenauer B, Judd M, Cranney A, et al. Infliximab for the treatment of rheumatoid arthritis (Cochrane review). In: The Cochrane Library. Wiley, Chichester, UK.
43. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet. 1999; 354: 1932-1939.
44. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis and Rheumatism. 1998; 41: 1552-1556.
45. U.S. Food and Drug Administration. Questions and answers - TNF blockers. August 2009. Available at http://www.fda.gov (accessed on 15 June 2012).
46. Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Annals of the Rheumatic Diseases. 2011; 70: 1895-1904.
47. Lazzerini PE, Acampa M, Hammoud M, et al. Arrhythmic risk during acute infusion of infliximab: a prospective, single-blind, placebo-controlled, crossover study in patients with chronic arthritis. Journal of Rheumatology. 2008; 35: 1958-1965.
48. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated With anti–TNF agents. Journal of the American Medical Association. 2009; 301: 737-744.
49. O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. New England of Journal Medicine. 1996; 334: 1287–1291.
50. O'Dell JR, Leff R, Paulsen G, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism. 2002; 46: 1164-1170.
51. Weinblatt ME, Schiff MH, Ruderman EM, et al. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. Arthritis and Rheumatism. 2008.; 58: 1921-30.
52. Gotzsche PC, Podenphant J, Olesen M, et al. Meta-analysis of second-line antirheumatic drugs: sample size bias and uncertain benefit. Journal of Clinical Epidemiology. 1992; 45: 587-594.
53. Cohen S, Cannon GW, Schiff M, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis and Rheumatism. 2001; 44: 1984-1992.
54. Strand V, Tugwell P, Bombardier C, et al. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis and Rheumatology. 1999; 42: 1870-1878.
55. Hewitson PJ, Debroe S, McBride A, et al. Leflunomide and rheumatoid arthritis: a systematic review of effectiveness, safety and cost implications. Journal of Clinical Pharmacy and Therapeutics. 2000; 25: 295-302.
56. Osiri M, Robinson VA, Shea BJ, et al. Leflunomide for treating rheumatoid arthritis. In: The Cochrane Library. Wiley, Chichester, UK.
57. Harth M. Mechanisms of action of disease modifying antirheumatic drugs. Journal of Rheumatology. 1992; 9: 100-103.
58. Mladenovic V, Domljan Z, Rozman B, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: results of a randomized, placebo-controlled, phase II study. Arthritis and Rheumatism. 1995; 38: 1595-1603.
59. Suarez-Almazor ME, Spooner C, Belseck E. Penicillamine for treating rheumatoid arthritis (Cochrane review). In: The Cochrane Library. Wiley, Chichester, UK.
60. van Rijthoven AW, Dijkmans BA, Goie The HS, et al. Comparison of cyclosporine and D-penicillamine for rheumatoid arthritis: a randomized, double blind, multicenter study. Journal of Rheumatology. 1991; 18: 815-820.
61. Paulus HE, Williams HJ, Ward JR, et al. Azathioprine versus D-penicillamine in rheumatoid arthritis patients who have been treated unsuccessfully with gold. Arthritis and Rheumatism. 1984; 27: 721–727.
62. Suarez-Almazor ME, Spooner CH, et al. Auranofin versus placebo in rheumatoid arthritis. In: The Cochrane Library. Update Software, Oxford, UK.
63. Clark P, Casas E, Tugwell P, et al. Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial. Annals of Internal Medicine. 1993; 119: 1067-1071.
64. Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Seminars in Arthritis and Rheumatism. 1993; 23 (supplement 1): S82-S91.
65. The HERA study group. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study. American Journal of Medicine. 1995; 98: 156-168.
66. The HERA Study Group. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study. American Journal of Medicine. 1995; 98: 156-168.
67. Criswell LA, Robinson VA, Saag KKS, et al. Moderate-term, low-dose corticosteroids for rheumatoid arthritis. In: The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd.
68. Choy EH, Smith CM, Farewell V, et al. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Annals of the Rheumatic Diseases. 2008; 67: 656-63.
69. Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Annals of Internal Medicine. 2012; 156: 329-39.
70. Verhoeven AC, Boers M. Limited bone loss due to corticosteroids: a systematic review of prospective studies in rheumatoid arthritis and other diseases. Journal of Rheumatology. 1997; 24: 1495-1503.
71. Medicines and Healthcare products Regulatory Agency. Drug safety update: latest advice for medicines users. Volume 1, issue 2, September 2007. November 2008. Available at http://www.mhra.gov.uk (accessed on 8 July 2011).
72. Hickling P, Jacoby RK, Kirwan JR. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. British Journal of Rheumatology. 1998; 37: 930-933.
73. Criswell LA, Saag KG, Sems KM, et al. Moderate-term, low-dose corticosteroids for rheumatoid arthritis (Cochrane review). In: The Cochrane Library. Update Software, Oxford, UK.
74. Gotzsche PC, Johansen HK. Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. BMJ. 1998; 316: 811-818.
75. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. New England Journal of Medicine. 1999; 340: 253-259.
76. Blumenauer B, Judd M, Cranney A, et al. Etanercept for the treatment of rheumatoid arthritis (Cochrane review). In: The Cochrane Library. Wiley, Chichester, UK.
77. Klareskog L, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004; 363: 675-681.
78. van Riel PL, Freundlich B, MacPeek D, et al. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial. Annals of the Rheumatic Diseases. 2008; 67: 1104-10.
79. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Annals of Internal Medicine. 1999; 130: 478-486.
80. U.S. Food and Drug Administration. Enbrel (etanercept) for subcutaneous injection. July 2008. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm121962.htm (accessed on 15 June 2012).
81. Amgen and Wyeth. Letter to healthcare professionals March 2008: Tuberculosis and infections with Enbrel® (etanercept). March 2008. Available at http://www.fda.gov (accessed on 15 June 2012).
82. Suarez-Almazor ME, Belseck E, Shea B, et al. Antimalarials for treating rheumatoid arthritis (Cochrane review). In: The Cochrane Library. Update Software, Oxford, UK.
83. Alarcon GS, Lopez-Mendez A, Walter J, et al Radiographic evidence of disease progression in methotrexate treated and nonmethotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients: a meta-analysis. Journal of Rheumatology. 1992; 19(12): 1868-1873.
84. Ahern MJ, Harrison W, Hollingsworth P, et al. A randomised double-blind trial of cyclosporin and azathioprine in refractory rheumatoid arthritis. Australian and New Zealand Journal of Medicine. 1991; 21: 844–849.
85. Kruger K, Schattenkirchner M. Comparison of cyclosporin A and azathioprine in the treatment of rheumatoid arthritis – results of a double-blind multicentre study. Clinical Rheumatology. 1994; 13: 248-255.
86. Wells G, Haguenauer D, Shea B, et al. Cyclosporine for rheumatoid arthritis (Cochrane review). In: The Cochrane Library. Update Software, Oxford, UK.
87. Clark P, Tugwell P, Bennet K, et al. Injectable gold for rheumatoid arthritis (Cochrane review). In: The Cochrane Library. Update Software, Oxford, UK.
88. Chaffman M, Brogden RN, Heel RC, et al. Auranofin: a preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis. Drugs. 1984; 27: 378-424.
89. Suarez-Almazor ME, Belseck E, Shea B, et al. Cyclophosphamide for rheumatoid arthritis (Cochrane review). In: The Cochrane Library. Wiley, Chichester, UK.
90. Radis CD, Kahl LE, Baker GL, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis: a 20-year follow-up study. Arthritis and Rheumatism. 1995; 38: 1120-1127.
91. Currey HL, Harris J, Mason RM, et al. Comparison of azathioprine, cyclophosphamide, and gold in treatment of rheumatoid arthritis. BMJ. 1974; 3: 763–766.
92. den Broeder A, van de Putte L, Rau R, et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. Journal of Rheumatology. 2002; 29: 2288–2298.
93. van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Annals of Rheumatic Diseases. 2004; 63: 508-516.
94. van de Putte LB, Rau R, Breedveld FC, et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Annals of Rheumatic Diseases. 2003; 62: 1168–1177.
95. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis and Rheumatism. 1998; 41: 2196–2204.
96. Bresnihan B, Newmark R, Robbins S, et al. Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. Journal of Rheumatology. 2004; 31: 1103-1111.
97. Nuki G, Bresnihan B, Bear MB, et al. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism. 2002; 46: 2838-2846.
98. Mertens M, Singh JA. Anakinra for rheumatoid arthritis. In: The Cochrane Library. Wiley, Chichester, UK.
99. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Annals of the Rheumatic Diseases. 2009; 68: 25-32.
100. National Institute for Health and Clinical Excellence. Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor. October 2011. Technology appraisals TA19. Available at http://www.nice.org.uk/TA195 (accessed on 15 June 2012).
101. Rigby W, Ferraccioli G, Greenwald M. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Care & Research. 2011; 63: 711-720.
102. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis and Rheumatism. 2006; 54: 2793-2806.
103. British National Formulary. Anti-lymphocyte monoclonal antibodies: rituximab and alemtuzumab. Section 8.2.3. British Medical Association and Royal Pharmaceutical Society of Great Britain. Also available at http://bnf.org (accessed on 15 June 2012).
104. Roche Products Limited. Direct healthcare professional communication on the association of MabThera (rituximab) with fatal infusion related reactions in patients with rheumatoid arthritis. September 2009. Available at http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---September/06/Direct-Healthcare-Professional-Communication-on-the-association-of-rituximab-with-fatal-infusion-related-reactions-in-patients-with-rheumatoid-arthritis (accessed on 15 June 2012).
105. Medicines and Healthcare products Regulatory Agency. Information sent to healthcare professionals in November 2008 about the safety of medicines. November 2008. Available at http://www.mhra.gov.uk (accessed on 15 June 2012).
106. Hadjinicolaou AV, Nisar MK, Bhagat S, et al. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review. Rheumatology. 2011; 50: 2297-2305.
107. National Institute for Health and Clinical Excellence. Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor. October 2011. Technology appraisals TA19. Available at http://www.nice.org.uk/TA195 (accessed on 15 June 2012).
108. Kremer JM, Genant HK, Moreland LW et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Annals of Internal Medicine. 2006; 144: 865-876.
109. Electronic Medicines Compendium. Orencia 250 mg powder for concentrate for solution for infusion. July 2010. Available at http://emc.medicines.org.uk (accessed on 8 July 2011).
110. Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet. 2007; 370: 1861-1874.
111. National Institute for Health and Clinical Excellence. Tocilizumab for rheumatoid arthritis. February 2012. Technology appraisal 198. Available at http://www.nice.org.uk/ta198 (accessed on 15 June 2012).
112. European Medicines Agency. RoActemra: summary of product characteristics. May 2011. Available at http://www.ema.europa.eu (accessed on 15 June 2012).
113. National Institute for Health and Clinical Excellence. Rheumatoid arthritis - certolizumab pegol. October 2011. Technology appraisal 186. Available at http://guidance.nice.org.uk/TA186 (accessed on 15 June 2012).
114. European Medicines Agency. Cimzia: summary of product characteristics. Available at http://www.ema.europa.eu (accessed on 15 June 2012).
115. National Institute for Health and Clinical Excellence. Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs. May 2012. Technology appraisal 225. Available at http://www.nice.org.uk/ta225 (accessed on 15 June 2012).
116. European Medicines Agency. Simponi: summary of product characteristics. March 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000992/WC500052368.pdf (accessed on 15 June 2012).
117. Medicines and Healthcare products Regulatory Agency. Drug safety update: volume 1, issue 12. July 2008. July 2010. Available at http://www.mhra.gov.uk (accessed on 15 June 2012).
118. National Institute for Clinical Excellence. Rheumatoid arthritis: the management of rheumatoid arthritis in adults. May 2012. Clinical guideline 79. Available at http://www.nice.org.uk/cg79 (accessed on 15 June 2012).
119. British National Formulary. Non-steroidal anti-inflammatory drugs. Section 10.1.1. British Medical Association and Royal Pharmaceutical Society of Great Britain. Also available at http://bnf.org (accessed on 29 May 2012).
120. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? BMJ. 2006; 332: 1302-1308.
121. Medicines and Healthcare products Regulatory Agency. Cardiovascular safety of COX-2 inhibitors and non-selective NSAIDs. July 2010. Available at http://www.mhra.gov.uk (accessed on 15 June 2012).
122. British National Formulary. Non-steroidal anti-inflammatory drugs: etoricoxib. Section 10.1.1. British Medical Association and Royal Pharmaceutical Society of Great Britain. Also available at http://bnf.org (accessed on 11 July 2011).
123. Haag MD, Bos MJ, Hofman A, et al. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. Archives of Internal Medicine. 2008; 168: 1219-1224.
124. European Medicines Agency. Questions and Answers on the review of non-selective NSAIDs. September 2006. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500017363.pdf (accessed on 15 June 2012).
125. Westby MD. A health professionals guide to exercise prescription for people with arthritis: a review of aerobic fitness activities. Arthritis and Rheumatism. 2001; 45: 501-511.
126. Resnick B. Managing arthritis with exercise. Geriatric Nursing. 2001; 22: 143-150.
127. Van den Ende CHM, Munneke M, Hazes JMW. Dynamic exercise therapy for treating rheumatoid arthritis (Cochrane review). In: The Cochrane Library. Update Software, Oxford, UK.
128. Tidow-Kebritchi S, Mobarhan S. Effects of diets containing fish oil and vitamin E on rheumatoid arthritis. Nutrition Reviews. 2001; 59: 335-338.

Citations